Skip to main content

Drug Interactions between tovorafenib and TPOXX

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tecovirimat tovorafenib

Applies to: TPOXX (tecovirimat) and tovorafenib

MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations and effects of tovorafenib, which has been found in vitro to be primarily metabolized by CYP450 2C8 and aldehyde oxidase, and to a lesser extent, by the isoenzymes CYP450 3A, 2C9, and 2C19. Increased plasma concentrations may increase the risk for adverse drug reactions including but not limited to, hemorrhage, skin toxicity, photosensitivity, hepatotoxicity, and reduced growth velocity in patients 18 years of age or younger. However, data from formal clinical drug interaction studies are not available.

MANAGEMENT: Caution is advised if tovorafenib is prescribed in combination with CYP450 2C8 inhibitors. Patients should be monitored for the development of hemorrhage, skin toxicity, photosensitivity, hepatotoxicity, and, in patients 18 years of age or younger, reduced growth velocity. Alternative therapy may need to be considered if a drug interaction is suspected.

References (1)
  1. (2024) "Product Information. Ojemda (tovorafenib)." Day One Biopharmaceuticals, Inc.

Drug and food interactions

Moderate

tecovirimat food

Applies to: TPOXX (tecovirimat)

ADJUST DOSING INTERVAL: Food may increase the extent of tecovirimat absorption following oral administration. When the recommended oral dose of tecovirimat (600 mg every 12 hours) was administered with a meal (approximately 600 calories and 25 g of fat) in healthy adults weighing less than 120 kg, tecovirimat absorption increased by 39% relative to fasting.

MANAGEMENT: Oral tecovirimat should be taken within 30 minutes after a full meal containing moderate or high fat (approximately 600 calories and 25 g of fat) with 6 to 8 ounces of water.

References (1)
  1. "Product Information. Tpoxx (tecovirimat)." SIGA Technologies, Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer